Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- COPD Treatments, Smoking Cessation Aids to Show Double-Digit Growth: Fuji-Keizai
November 1, 2010
- Mediscience: FY2010 Business Results Fall Short of Forecasts
November 1, 2010
- IMSUT Objects to Asahi Shimbun News
November 1, 2010
- JMA, JAMS Oppose JSLN's Cholesterol GL for Longevity
November 1, 2010
- Eli Lilly Japan to Target Orthopedic Surgeons in Promoting Forteo
October 25, 2010
- Continued Sales of Ketoprofen Products Should Be Permitted: CDFS
October 25, 2010
- Allermist Improves Ophthalmic Allergic Symptoms: Prof. Kurono
October 25, 2010
- CSO Market to Grow at 14.4% in FY2010 and Onward: MIC Research
October 25, 2010
- Original Itraconazole Product Shows Inter-Lot Differences
October 25, 2010
- 2 Kohdo-iryo Recommended for Use under Health Insurance Programs
October 25, 2010
- Price Settlement Rate 17.9% as of September at NPhA Members
October 25, 2010
- Takeda Licenses Cervical Cancer Vaccine from JHSF
October 25, 2010
- Free Coupons for Cervical, Breast Cancer Exam Used by About 20% of Eligible Women
October 25, 2010
- Gilead's HBV Drug Licensed to GSK in Japan
October 25, 2010
- BIBW 2992 Extends PFS in NSCLC Patients: BI
October 25, 2010
- Risk Classification for 7 APIs Reviewed
October 25, 2010
- CMIC, Fujirebio to Collaborate to Market RENAPRO L-FABP Test
October 25, 2010
- US, EU Submissions for BSI-201 for mTNBC in 2011
October 25, 2010
- Chugai's Alliance with Roche Enters 2nd Phase
October 25, 2010
- Takepron Ranked No. 1 in HP Market: RepTrack Survey
October 25, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…